{
  "main_header": {
    "sid": 189669,
    "name": "Kilitch Drugs",
    "stock_name": "Kilitch Drugs",
    "full_name": "Kilitch Drugs (India) Ltd",
    "name_url": "stocks-analysis/kilitch-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "331.50",
    "chg": -13.5,
    "chgp": "-3.91%",
    "dir": -1,
    "prev_price": "345.00",
    "mcapval": "547.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524500,
    "symbol": "KILITCH",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE729D01010",
    "curr_date": "Apr 11, 12:51 PM",
    "curr_time": "01:29 AM",
    "bse_nse_vol": "1.68 k",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/kilitch-drugs-189669-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Kilitch Drugs Faces Mixed Technical Trends Amidst Market Challenges and Long-Term Resilience",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-technical-trend-shifts-from-mildly-bullish-to-sideways-amid-price-decline-1669827",
        "imagepath": "",
        "date": "2025-04-02 08:01:11",
        "description": "Kilitch Drugs (India), a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 358.75, slightly down from the previous close of 362.95. Over the past year, Kilitch Drugs has experienced a 5.75% decline, contrasting with a 2.72% gain in the Sensex, indicating a challenging year relative to the broader market.\n\nIn terms of technical indicators, the weekly MACD remains bullish, while the monthly outlook shows a mildly bearish trend. The Relative Strength Index (RSI) indicates no significant signals for both weekly and monthly periods. Bollinger Bands suggest a mildly bullish sentiment on both weekly and monthly charts, while moving averages present a mildly bearish stance on a daily basis. The KST shows a bullish trend weekly but leans mildly bearish monthly.\n\nNotably, Kilitch Drugs has dem..."
      },
      {
        "title": "Kilitch Drugs Shows Mixed Technical Trends Amidst Market Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-technical-trend-shifts-from-sideways-to-mildly-bullish-amid-mixed-outlook-1598284",
        "imagepath": "",
        "date": "2025-03-26 08:00:27",
        "description": "Kilitch Drugs (India), a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 348.25, slightly down from the previous close of 350.60. Over the past year, Kilitch Drugs has experienced a 4.81% decline, contrasting with a 7.12% gain in the Sensex, highlighting the stock's relative underperformance in the short term.\n\nHowever, a closer look at the company's technical indicators reveals a mixed picture. The MACD shows a mildly bullish trend on a weekly basis, while the monthly perspective leans mildly bearish. The Bollinger Bands indicate a mildly bullish stance weekly and bullish monthly, suggesting some positive momentum. Additionally, the On-Balance Volume (OBV) reflects a bullish trend, reinforcing the notion of underlying strength.\n\nIn terms of returns, Kilitch Drugs has outperformed ..."
      },
      {
        "title": "Kilitch Drugs Faces Mixed Technical Trends Amid Market Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-technical-trend-shifts-from-mildly-bullish-to-sideways-amid-mixed-indicators-1575543",
        "imagepath": "",
        "date": "2025-03-25 08:00:38",
        "description": "Kilitch Drugs (India), a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 350.60, down from a previous close of 355.85. Over the past year, Kilitch Drugs has experienced a 4.17% decline, contrasting with a 7.07% gain in the Sensex, highlighting the stock's relative underperformance in the broader market context.\n\nThe technical summary indicates a mixed performance across various indicators. The MACD shows a mildly bullish trend on a weekly basis, while the monthly perspective leans mildly bearish. The Bollinger Bands reflect a mildly bullish stance weekly and bullish monthly, suggesting some volatility in price movements. Moving averages indicate a mildly bearish trend on a daily basis, while the KST presents a similar mildly bullish outlook weekly and mildly bearish monthly.\n\nIn te..."
      },
      {
        "title": "Kilitch Drugs Experiences Technical Trend Shifts Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-technical-trend-shifts-from-sideways-to-mildly-bullish-amid-price-increase-1572802",
        "imagepath": "",
        "date": "2025-03-24 08:00:18",
        "description": "Kilitch Drugs (India), a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 355.85, showing a notable increase from the previous close of 348.50. Over the past week, Kilitch Drugs has demonstrated a strong performance, with a return of 12.97%, significantly outpacing the Sensex's return of 4.17% during the same period.\n\nThe technical summary indicates a mixed outlook, with the MACD showing mildly bullish signals on a weekly basis, while the monthly perspective leans mildly bearish. The Bollinger Bands reflect bullish trends on both weekly and monthly charts, suggesting potential volatility. Additionally, the On-Balance Volume (OBV) is bullish on both timeframes, indicating positive trading volume trends.\n\nKilitch Drugs has also shown impressive long-term performance, with a staggering..."
      },
      {
        "title": "Kilitch Drugs Adjusts Valuation Amidst Mixed Stock Performance and Competitive Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-valuation-grade-changes-from-fair-to-expensive-amid-stock-price-increase-1542215",
        "imagepath": "",
        "date": "2025-03-21 08:00:07",
        "description": "Kilitch Drugs (India), a microcap player in the pharmaceuticals and drugs sector, has recently undergone a valuation adjustment. The company's current price stands at 348.50, reflecting a notable increase from the previous close of 334.60. Over the past year, Kilitch Drugs has experienced a stock return of -0.99%, contrasting with a 5.89% return from the Sensex. However, the company has shown strong performance over longer periods, with a remarkable 305.23% return over five years, significantly outpacing the Sensex's 155.21% during the same timeframe.\n\nKey financial metrics for Kilitch Drugs include a PE ratio of 28.73 and an EV to EBITDA ratio of 22.66. The company's return on capital employed (ROCE) is reported at 8.53%, while the return on equity (ROE) stands at 8.69%. When compared to its peers, Kilitch Drugs maintains a competitive position, although its valuation metrics indicate a higher relative val..."
      },
      {
        "title": "Kilitch Drugs Faces Mixed Technical Trends Amid Market Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-india-technical-trend-shifts-from-mildly-bearish-to-sideways-amid-mixed-indicators-1494232",
        "imagepath": "",
        "date": "2025-03-20 08:00:29",
        "description": "Kilitch Drugs (India), a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 334.60, slightly down from the previous close of 335.40. Over the past year, Kilitch Drugs has experienced a decline of 3.66%, contrasting with a 4.77% gain in the Sensex, highlighting the stock's underperformance relative to the broader market.\n\nIn terms of technical indicators, the weekly MACD shows a mildly bullish trend, while the monthly perspective leans mildly bearish. The Relative Strength Index (RSI) indicates no significant signals for both weekly and monthly assessments. Bollinger Bands are bullish on both time frames, suggesting potential price stability. However, moving averages present a mildly bearish outlook on a daily basis, and the KST reflects a bearish trend in both weekly and monthly evalu..."
      },
      {
        "title": "Kilitch Drugs Shows Mixed Technical Trends Amid Strong Long-Term Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-india-technical-trend-shifts-from-bearish-to-mildly-bearish-amid-stock-price-increase-1463083",
        "imagepath": "",
        "date": "2025-03-19 08:00:29",
        "description": "Kilitch Drugs (India), a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 335.40, showing a notable increase from the previous close of 321.50. Over the past week, Kilitch Drugs has demonstrated a stock return of 10.17%, significantly outperforming the Sensex, which returned 1.62% in the same period.\n\nIn terms of technical indicators, the weekly MACD suggests a mildly bullish sentiment, while the monthly perspective leans towards a mildly bearish outlook. The Bollinger Bands indicate bullish trends on both weekly and monthly charts, suggesting some volatility but overall positive momentum. However, moving averages and other indicators like KST and OBV reflect a mildly bearish stance on a daily basis.\n\nKilitch Drugs has shown resilience over longer periods, with a remarkable 273.08% re..."
      },
      {
        "title": "Kilitch Drugs Reports Strong Sales Growth Amid Management Efficiency Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kilitch-drugs-reports-43-05-operating-profit-growth-amid-low-roe-and-market-underperformance-1450351",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/KilitchDrugsInd_mojoScore_702305.png",
        "date": "2025-03-19 08:00:12",
        "description": "Kilitch Drugs (India) has recently adjusted its evaluation, reflecting strong financial performance with an 18.33% increase in net sales and a 43.05% rise in operating profit for the quarter ending December 2024. However, challenges in management efficiency and stock performance persist despite rising profits."
      },
      {
        "title": "Kilitch Drugs Reports Strong Sales Growth Amidst Mixed Financial Indicators and Market Sentiment",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kilitch-drugs-faces-stock-downgrade-despite-strong-financial-performance-and-low-debt-ratio-1270067",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/KilitchDrugsInd_mojoScore_636968.png",
        "date": "2025-03-11 08:00:29",
        "description": "Kilitch Drugs (India) has recently experienced a change in evaluation following its strong financial performance for the quarter ending December 2024, marked by an 18.33% increase in net sales and a 44.8% rise in profit after tax. However, challenges remain, including a low return on equity and underperformance compared to the broader market."
      }
    ],
    "total": 42,
    "sid": "189669",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/kilitch-drugs-india-189669"
  },
  "announcements": [
    {
      "caption": "Reply To Query LODR Regarding Completion Of Tenure Of Independent Director",
      "datetime": "09-Apr-2025",
      "details": "We herewith attached our reply",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Retirement",
      "datetime": "07-Apr-2025",
      "details": "We hereby inform you that Mr. Hemang Jagadish Engineer has completed his secon term as Independent Director of the Company on 31st March 2025",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "26-Mar-2025",
      "details": "Trading Window for dealing in securities of the Company will remain closed for all the Designated Persons of the Company with effect from Tuesday 1st April 2025 till expiry of 48 hours after declaration of Financial Results of the Company",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Kilitch Drugs (India) Ltd has declared <strong>5%</strong> dividend, ex-date: 20 Sep 19",
          "dt": "2019-09-20",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Kilitch Drugs Faces Mixed Technical Trends Amidst Market Challenges and Long-Term Resilience

2025-04-02 08:01:11

Kilitch Drugs (India), a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 358.75, slightly down from the previous close of 362.95. Over the past year, Kilitch Drugs has experienced a 5.75% decline, contrasting with a 2.72% gain in the Sensex, indicating a challenging year relative to the broader market. In terms of technical indicators, the weekly MACD remains bullish, while the monthly outlook shows a mildly bearish trend. The Relative Strength Index (RSI) indicates no significant signals for both weekly and monthly periods. Bollinger Bands suggest a mildly bullish sentiment on both weekly and monthly charts, while moving averages present a mildly bearish stance on a daily basis. The KST shows a bullish trend weekly but leans mildly bearish monthly. Notably, Kilitch Drugs has dem...

Read More

Kilitch Drugs Shows Mixed Technical Trends Amidst Market Underperformance

2025-03-26 08:00:27

Kilitch Drugs (India), a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 348.25, slightly down from the previous close of 350.60. Over the past year, Kilitch Drugs has experienced a 4.81% decline, contrasting with a 7.12% gain in the Sensex, highlighting the stock's relative underperformance in the short term. However, a closer look at the company's technical indicators reveals a mixed picture. The MACD shows a mildly bullish trend on a weekly basis, while the monthly perspective leans mildly bearish. The Bollinger Bands indicate a mildly bullish stance weekly and bullish monthly, suggesting some positive momentum. Additionally, the On-Balance Volume (OBV) reflects a bullish trend, reinforcing the notion of underlying strength. In terms of returns, Kilitch Drugs has outperformed ...

Read More

Kilitch Drugs Faces Mixed Technical Trends Amid Market Underperformance

2025-03-25 08:00:38

Kilitch Drugs (India), a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 350.60, down from a previous close of 355.85. Over the past year, Kilitch Drugs has experienced a 4.17% decline, contrasting with a 7.07% gain in the Sensex, highlighting the stock's relative underperformance in the broader market context. The technical summary indicates a mixed performance across various indicators. The MACD shows a mildly bullish trend on a weekly basis, while the monthly perspective leans mildly bearish. The Bollinger Bands reflect a mildly bullish stance weekly and bullish monthly, suggesting some volatility in price movements. Moving averages indicate a mildly bearish trend on a daily basis, while the KST presents a similar mildly bullish outlook weekly and mildly bearish monthly. In te...

Read More

Kilitch Drugs Experiences Technical Trend Shifts Amid Strong Market Performance

2025-03-24 08:00:18

Kilitch Drugs (India), a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 355.85, showing a notable increase from the previous close of 348.50. Over the past week, Kilitch Drugs has demonstrated a strong performance, with a return of 12.97%, significantly outpacing the Sensex's return of 4.17% during the same period. The technical summary indicates a mixed outlook, with the MACD showing mildly bullish signals on a weekly basis, while the monthly perspective leans mildly bearish. The Bollinger Bands reflect bullish trends on both weekly and monthly charts, suggesting potential volatility. Additionally, the On-Balance Volume (OBV) is bullish on both timeframes, indicating positive trading volume trends. Kilitch Drugs has also shown impressive long-term performance, with a staggering...

Read More

Kilitch Drugs Adjusts Valuation Amidst Mixed Stock Performance and Competitive Metrics

2025-03-21 08:00:07

Kilitch Drugs (India), a microcap player in the pharmaceuticals and drugs sector, has recently undergone a valuation adjustment. The company's current price stands at 348.50, reflecting a notable increase from the previous close of 334.60. Over the past year, Kilitch Drugs has experienced a stock return of -0.99%, contrasting with a 5.89% return from the Sensex. However, the company has shown strong performance over longer periods, with a remarkable 305.23% return over five years, significantly outpacing the Sensex's 155.21% during the same timeframe. Key financial metrics for Kilitch Drugs include a PE ratio of 28.73 and an EV to EBITDA ratio of 22.66. The company's return on capital employed (ROCE) is reported at 8.53%, while the return on equity (ROE) stands at 8.69%. When compared to its peers, Kilitch Drugs maintains a competitive position, although its valuation metrics indicate a higher relative val...

Read More

Kilitch Drugs Faces Mixed Technical Trends Amid Market Underperformance

2025-03-20 08:00:29

Kilitch Drugs (India), a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 334.60, slightly down from the previous close of 335.40. Over the past year, Kilitch Drugs has experienced a decline of 3.66%, contrasting with a 4.77% gain in the Sensex, highlighting the stock's underperformance relative to the broader market. In terms of technical indicators, the weekly MACD shows a mildly bullish trend, while the monthly perspective leans mildly bearish. The Relative Strength Index (RSI) indicates no significant signals for both weekly and monthly assessments. Bollinger Bands are bullish on both time frames, suggesting potential price stability. However, moving averages present a mildly bearish outlook on a daily basis, and the KST reflects a bearish trend in both weekly and monthly evalu...

Read More

Kilitch Drugs Shows Mixed Technical Trends Amid Strong Long-Term Performance

2025-03-19 08:00:29

Kilitch Drugs (India), a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 335.40, showing a notable increase from the previous close of 321.50. Over the past week, Kilitch Drugs has demonstrated a stock return of 10.17%, significantly outperforming the Sensex, which returned 1.62% in the same period. In terms of technical indicators, the weekly MACD suggests a mildly bullish sentiment, while the monthly perspective leans towards a mildly bearish outlook. The Bollinger Bands indicate bullish trends on both weekly and monthly charts, suggesting some volatility but overall positive momentum. However, moving averages and other indicators like KST and OBV reflect a mildly bearish stance on a daily basis. Kilitch Drugs has shown resilience over longer periods, with a remarkable 273.08% re...

Read More

Kilitch Drugs Reports Strong Sales Growth Amid Management Efficiency Challenges

2025-03-19 08:00:12

Kilitch Drugs (India) has recently adjusted its evaluation, reflecting strong financial performance with an 18.33% increase in net sales and a 43.05% rise in operating profit for the quarter ending December 2024. However, challenges in management efficiency and stock performance persist despite rising profits.

Read More

Kilitch Drugs Reports Strong Sales Growth Amidst Mixed Financial Indicators and Market Sentiment

2025-03-11 08:00:29

Kilitch Drugs (India) has recently experienced a change in evaluation following its strong financial performance for the quarter ending December 2024, marked by an 18.33% increase in net sales and a 44.8% rise in profit after tax. However, challenges remain, including a low return on equity and underperformance compared to the broader market.

Read More

View All News